🚀 Sign up Free for Public Company Valuation & Insights!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free Video Highlights
AbbVie 
Pharma / Pharma
At a Glance | Core Facts | Company Due Diligence: | Industry Due Diligence: | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | Web1. Dependence on Humira: Humira represents a large portion of AbbVie's revenue. If the drug loses patent exclusivity, AbbVie could suffer a significant drop in revenue.
2. Competition: There is increasing competition in the biopharmaceuticals space, which could limit AbbVie's opportunity for growth.
3. Regulatory Risk: AbbVie must comply with stringent global regulations in order to bring new drugs to market, or risk costly fines.
4. Acquisition Risk: Acquisitions are risky for any company, and AbbVie is no exception. Acquiring smaller companies or entering new markets could result in unforeseen costs or timing delays.
Wait! There's more — sign up for free or log in